Stay updated with breaking news from Nasdaq Cbay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Moody Aldrich Partners LLC bought a new stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 115,340 shares of the biopharmaceutical company’s stock, valued at approximately $1,263,000. A number of other hedge […]
CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price target lifted by UBS Group from $18.00 to $25.00 in a research report sent to investors on Tuesday, Marketbeat.com reports. They currently have a buy rating on the biopharmaceutical company’s stock. CBAY has been the topic of several other reports. Cantor Fitzgerald reissued an overweight rating […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) insider Charles Mcwherter sold 21,746 shares of the firm’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $16.22, for a total value of $352,720.12. Following the sale, the insider now directly owns 15,000 shares of the company’s stock, […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) General Counsel Paul T. Quinlan sold 53,000 shares of the company’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $16.87, for a total transaction of $894,110.00. The transaction was disclosed in a document filed with the Securities & […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 8,960,000 shares, a decrease of 21.1% from the August 15th total of 11,350,000 shares. Based on an average daily volume of 2,410,000 shares, […]